A double-blind, placebo-controlled trial of pegylated recombinant human megakaryocyte growth and development factor as an adjunct to induction and consolidation therapy for patients with acute myeloid leukemia

Blood

Volumn 95, Issue 8, 2000, Pages 2530-2535

  Schiffer, Charles A ^a   Miller, Kenneth ^b   Larson, Richard A ^b   Amrein, Philip C ^b   Antin, Joseph H ^b   Zani, Valter J ^b   Stone, Richard M ^b  

^a HARPER UNIVERSITY HOSPITAL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYTARABINE; DAUNORUBICIN; RECOMBINANT MEGAKARYOCYTE GROWTH AND DEVELOPMENT FACTOR;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG RESPONSE; DRUG TOLERABILITY; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTE COUNT; THROMBOCYTE TRANSFUSION;

EID: 0034655649     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v95.8.2530.008k31_2530_2535     Document Type: Article

References (30)

1. Kaushansky K. Thrombopoietin: the primary regulator of platelet production. Blood. 1995;86: 419-431.
2. de Sauvage FJ, Hass PE, Spencer SD, et al. Stimulation of megakaryocytopoiesis and thrombopoiesis by the c-Mpl ligand. Nature. 1994;369: 533-538.
3. Ulich T, del Castillo J, Yin S, et al. Megakaryocyte growth and development factor ameliorates carboplatin-induced thrombocytopenia in mice. Blood. 1995;86:971-976.
4. Farese AM, Hunt P, Boone TC, MacVittie TJ. Recombinant human megakaryocyte growth and development factor stimulates thrombocytopoiesis in normal non-human primates. Blood. 1995; 86:54-59.
5. Andrews RG, Winkler A, Myerson D, et al. Recombinant human ligand for MPL, megakaryocyte growth and development factor (MGDF) stimulates thrombopoiesis in vivo in normal and myelosuppressed baboons. Stem Cells. 1996;14: 661-677.
6. Harker LA, Marzec UM, Kelly AB, et al. Prevention of thrombocytopenia and neutropenia in a nonhuman primate model of marrow suppressive chemotherapy by combining pegylated recombinant human megakaryocyte growth and development factor and recombinant human granulocyte colony-stimulating factor. Blood. 1997;89:155-165.
7. Basser RL, Rasko JEJ, Clarke K, et al. Randomized, blinded, placebo-controlled phase I trial of pegylated recombinant human megakaryocyte growth and development factor with filgrastim after dose-intensive chemotherapy in patients with advanced cancer. Blood. 1997;89:3118-3128.
8. Vadhan-Raj S, Murray LJ, Bueso-Ramos C, et al. Stimulation of megakaryocyte and platelet production by a single dose of recombinant human thrombopoietin in patients with cancer. Ann Intern Med. 1997;26:673-681.
9. Kuter D, McCullough J, Romo J, et al. Treatment of platelet (PLT) donors with pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) increases circulating PLT counts (CTS) and PLT apheresis yields and increases platelet increments in recipients of PLT transfusions. Blood. 1997;90(suppl 1): 579a.
10. Fanucchi M, Glaspy J, Crawford J, et al. Effects of polyethylene glycol-conjugated recombinant human megakaryocyte growth and development factor on platelet counts after chemotherapy for lung cancer. N Engl J Med. 1997;336:404-409.
11. O'Malley CJ, Rasko JEJ, Basser RL, et al. Administration of pegylated recombinant human megakaryocyte growth and development factor to humans stimulates the production of functional platelets that show no evidence of in vivo activation. Blood. 1996;88:3288-3298.
12. Somlo G, Sniecinski I, ter Veer A, et al. Recombinant human thrombopoietin in combination with granulocyte colony stimulating factor enhances mobilization of peripheral blood progenitor cells, increases peripheral blood platelet concentration and accelerates hematopoietic recovery following high dose therapy. Blood. 1999;93:2798-2806.
13. Vigon I, Dreyfus F, Melle J, et al. Expression of the c-mpl Proto-oncogene in human hematologic malignancies. Blood. 1993;82:877-883.
14. Matsumura I, Kanakura Y, Kato T, Ikeda H, Ishikawa J, Horikawa Y. Growth response of acute myeloblastic leukemia cells to recombinant human thrombopoietin. Blood. 1995;86:703-709.
15. Mayer RJ, Davis RB, Schiffer CA, et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. N Engl J Med. 1994;331:896-903.
16. Mitus AJ, Miller KB, Schenkein D, et al. Improved survival for patients with acute myelogenous leukemia. J Clin Oncol. 1995;13:560-569.
17. Dale DC, Nichol JL, Rich DA, et al. Chronic thrombocytopenia is induced in dogs by development of cross-reacting antibodies to the MpL ligand. Blood. 1997;90:3456-3461.
18. Heddle JM, Klama L, Singer J, et al. The role of plasma from platelet concentrates in transfusion reactions. N Engl J Med. 1994;331:625-628.
19. Buchholz DH, Young VM, Friedman NR, Reilly JA, Mardiney MR. Bacterial proliferation in platelet products stored at room temperature. N Engl J Med. 1971;285:429-433.
20. Archimbaud E, Ottmann OG, Liu-Yan JA, et al. A randomized, double-blind, placebo controlled study with pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) as an adjunct to chemotherapy for adults with de novo acute myeloid leukemia. Blood. 1999;94:3694-3701.
21. The TRAP Study Group. Leukocyte reduction and UV-B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusion. N Engl J Med. 1997;337:1861-1869.
22. Schiffer CA. Hematopoietic growth factors as adjuncts to the treatment of acute myeloid leukemia. Blood. 1996;88:3675-3685.
23. Heil G, Hoelzer D, Sanz MA, et al. A randomized, double-blind, placebo-controlled, phase III study of filgrastim in remission induction and consolidation therapy for adults with de novo acute myeloid leukemia. The International Acute Myeloid Leukemia Study Group. Blood. 1997;90:4710-4718.
24. Emmons RVB, Reid DM, Cohen RL, et al. Human thrombopoietin levels are high when thrombocytopenia is due to megakaryocyte deficiency and low when due to increased platelet destruction. Blood. 1996;87:4068-4071.
25. Harousseau JL, Witz F, Desablens B, et al. G-CSF after intensive consolidation chemotherapy in acute myeloid leukemia. The Groupe Ouest Est Leucemies Aigues Myeloblastiques (GOELAM). Blood. 1997;90:(suppl 1):504a.
26. Rebulla P, Finazzi G, Marangoni F, et al. The threshold for prophylactic platelet transfusions in adults with acute myeloid leukemia. Gruppo Italiano Malattie Ematologiche Maligne Dell' Adulfo. N Engl J Med. 1997;337:1870-1875.
27. Heckman KD, Weiner GJ, Davis CS, Strauss RG, Jones MP, Bums CP. Randomized study of prophylactic platelet transfusion threshold during induction therapy for adult acute leukemia: 10,000/μL versus 20,000/μL. J Clin Oncol. 1997;15:1143-1149.
28. 9/L trigger for prophylactic platelet transfusions compared with the traditional 20 × 10(9)/L trigger: a prospective comparative trial in 105 patients with acute myeloid leukemia. Blood. 1998;91:3601-3606.
29. Glaspy J, Vredenburgh J, Demetri GD, et al. Effect of PEGylated recombinant megakaryocyte growth and development factor (PEG-rHuMGDF) before high dose chemotherapy with peripheral blood progenitor cell (PBPC) support. Blood. 1997;90(suppl 1):580a.
30. Kuter DJ, Cebon J, Harker LA, McCullough J. Platelet growth factors: potential impact on transfusion medicine. Transfusion. 1999;39:321-332.